Encouraging the use of generic medicines: Implications for transition economies

Croatian Medical Journal

Volumn 43, Issue 4, 2002, Pages 462-469

  King, Derek R ^a   Kanavos, Panos ^a,b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cost control; Drug industry; Drugs, generic; Health care rationing; Legislation, drug; Pharmaceutical preparations

Indexed keywords

GENERIC DRUG;

ARTICLE; CANADA; COST CONTROL; DECISION MAKING; DENMARK; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG QUALITY; DRUG USE; GERMANY; GOOD MANUFACTURING PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; INFORMATION SYSTEM; LAW; NETHERLANDS; PATENT; QUALITY CONTROL; REIMBURSEMENT; UNITED KINGDOM; UNITED STATES;

COST SAVINGS; DEVELOPING COUNTRIES; DRUGS, GENERIC; ECONOMIC COMPETITION; EUROPE; GREAT BRITAIN; HEALTH CARE RATIONING; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; UNITED STATES;

EID: 0036689918     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Dramatic increase in drug spending largely attributable to few costly medications
2. The management of the cost and utilisation of pharmaceuticals in the United Kingdom
3. Financing pharmaceuticals in transition economies
4. Increasing demand while decreasing costs of generic medicines
5. An evaluation of the PPRS: Is there a need for reform?
6. Patent expiration, entry, and competition in the US pharmaceutical industry: An exploratory analysis. Brookings papers on economic activity
7. Changes to Ontario Formulary will mean big savings for health care system
8. The German experience in reference pricing
9. Cost containment in the EU: An overview
10. Another war on drugs: European countries turn to 'reference pricing' in battle against soaring cost of pharmaceuticals
11. Review of the literature on reference pricing
12. Cost and utilisation of pharmaceuticals in Sweden
13. Interesting times in German health policy
14. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs
15. A comparative analysis of generic markets in five European countries
16. GP fundholding and the costs of prescribing: Further results
17. Alterations in prescribing by general practicioner fundholders: An observational study
18. Generic pharmaceuticals - Implications for the global pharmaceutical industry
19. A prescribing incentive scheme for non-fundholding general practices: An observational study
20. Changes in drug prescribing under the Public Health Reform Law - A survey of general practitioners' attitudes in East and West Germany
21. Fixed budgets in the pharmaceutical sector in Germany: Effects on costs and quality
22. Distribution margins: A European overview
23. Pharmaceutical coverage and resource allocation: Lessons for the US from pharmaceutical policies in the UK, France and Germany
24. Substitution laws, insurance coverage, and generic drug use
25. A physician survey on generic drugs and substitution of critical dose medications
26. A critical review of the remuneration system for pharmacists
27. Prescribing generic drugs
28. Hospital pharmacy decisions, cost containment and the use of cost-effectiveness analysis
29. HMOs generic substitution
30. The pros and cons of generic medicines
31. The globalization of pharmaceutical regulation